Conclusion of FDA’s 24/7 Drug Entry Review Pilot
Published Jun 10, 2022
Summary
FDA announced the conclusion of its 90-day Nationalized Drug Entry Review Pilot on June 11, 2022, ending 24/7 national drug entry admissibility reviews and shutting down the pilot's dedicated contact channels. FDA will analyze pilot data to assess potential improvements to the drug entry review process.
Summary is machine-generated at the linking layer for discovery only. Refer to the source bulletin for authoritative guidance.
CSMS 52132388 · full bulletinRelated bulletins
Consumer Product Safety Commission (CPSC) Implementation Guide and Partner Government Agency (PGA) Flag Enforcement Table Documents Updated on CBP.gov
Jul 28, 2026
Harmonized System Update (HSU) 2617
Jul 27, 2026
Harmonized System Update (HSU) 2616
Jul 23, 2026
Notice from the U.S. Fish and Wildlife Service regarding Final Rule Amending 50 CFR Part 10 Shellfish Definition and Updated Tariff Flagging
Jul 15, 2026
Harmonized System Update (HSU) 2615
Jul 14, 2026